Calgary, Alberta, April 16, 2020 – FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), is pleased to announce that it has entered into a strategic Agreement in Principle with Alberta BioPhotonics Inc. (“ABP”) and Albany Medical College (“AMC”) to form FluroTest LLC (“FluroTest”).
The CompleTestTM adaptation is expected to take approximately three months with trials planned shortly thereafter. The collaboration will have primary focus on adapting FluroTech’s CompleTestTM platform technology to test for a range of viruses including COVID-19, as well as accurately determining viral load. Additionally, FluroTest believes its technology can also be adapted to allow for the detection of specific anti-SARS-CoV-2 human antibodies in blood samples, potentially confirming the development of immunity. Once developed, both tests would be administered at point-of-collection with results expected to be available in less than 15 minutes.